Huntsman Carole 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Madrigal (MDGL) CCO Carole Huntsman Receives Awards; Sells Shares
What Happened
Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals (MDGL), was granted equity awards and had a small share sale. The Form 4 shows: a grant of 3,989 restricted stock units (RSUs) (acquired at $0.00), a grant of 4,986 derivative shares (acquired at $0.00, appears to be an option/other vesting award), and an open-market/private sale of 419 shares at $431.94 each, netting $180,983. The sale was reported as a withholding sale to cover taxes; the awards are subject to multi-year vesting schedules.
Key Details
- Transaction dates: grants dated March 4, 2026; sale reported March 6, 2026 (transaction dated March 4, 2026). Sale price: $431.94 per share; sale proceeds $180,983.
- Shares acquired: 3,989 RSUs and 4,986 derivative shares (grants valued at $0.00 on Form 4). Shares disposed: 419 shares.
- Shares owned after transaction: not specified in the filing.
- Notable footnotes:
- F1: The 3,989 RSUs vest 25% on each of March 4, 2027, 2028, 2029 and 2030, subject to continued service.
- F2: The 419-share sale was automatic — shares sold by the issuer on behalf of the reporting person to satisfy tax withholding related to vesting. It was not a discretionary market sale.
- F3: The 4,986 derivative award vests 25% on the first anniversary (March 4, 2027) and then 6.25% each quarter thereafter, contingent on continued service.
- Filing timeliness: Form filed March 6, 2026 covering March 4 transactions; this appears to be a timely Form 4 filing.
Context
The awards are typical time-based equity compensation (RSUs and a time-vesting derivative/option grant) that vest over about four years. The 419-share sale was an issuer-facilitated sale to cover tax withholding obligations tied to vesting — a routine administrative transaction rather than an independent sell decision. These filings are informational; they show grant terms and routine withholding transactions but do not, by themselves, indicate the insider's view of the company's stock.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-04+3,989→ 13,111 total - Sale
Common Stock
[F2]2026-03-06$431.94/sh−419$180,983→ 12,692 total - Award
Stock Option (Right to Buy)
[F3]2026-03-04+4,986→ 4,986 totalExercise: $434.80Exp: 2036-03-04→ Common Stock (4,986 underlying)
Footnotes (3)
- [F1]Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
- [F2]This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
- [F3]The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.